We are live on
!
Find out more
GPCM
Granite Point Capital Management Portfolio holdings
AUM
$4.9M
1-Year Est. Return
38.41%
This Fund
S&P 500
This Quarter
Est. Return
+2.1%
1 Year Est. Return
+38.41%
3 Year Est. Return
+124.67%
5 Year Est. Return
+295.96%
10 Year Est. Return
–
AUM
$125M
AUM Growth
-$131M
(-51%)
Cap. Flow
-$122M
Cap. Flow
% of AUM
-97.07%
Top 10 Holdings %
Top 10 Hldgs %
39.36%
Holding
112
New
21
Increased
21
Reduced
8
Closed
32
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$4.61M |
| 2 |
Axogen
AXGN
|
+$2.46M |
| 3 |
Aclaris Therapeutics
ACRS
|
+$2.42M |
| 4 |
Bank of America
BAC
|
+$2.41M |
| 5 |
HDSN
Hudson Technologies
HDSN
|
+$1.84M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$4.91M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$4.02M |
| 3 |
HIMX
Himax Technologies
HIMX
|
+$3.25M |
| 4 |
CY
Cypress Semiconductor
CY
|
+$2.13M |
| 5 |
MEET
The Meet Group, Inc. Common Stock
MEET
|
+$1.81M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 26.12% |
| 2 | Consumer Discretionary | 12.52% |
| 3 | Technology | 11.2% |
| 4 | Communication Services | 9.58% |
| 5 | Financials | 6.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
Invesco QQQ Trust
QQQ
$453B
| $8.29M | 6.61% |
70,000
-105,500
| -60% | -$12.4M |
|
|
ARIA
2
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $5.8M | 4.62% |
466,015
+8,600
| +2% | +$104K |
|
3
Shake Shack
SHAK
$2.53B
| $5.37M | 4.28% |
150,001
| – | – |
|
|
AERI
4
DELISTED
Aerie Pharmaceuticals
AERI
| $5.09M | 4.06% |
134,500
| – | – |
|
5
Meta Platforms (Facebook)
META
$1.42T
| $4.88M | 3.89% |
42,400
| – | – |
|
|
ADMS
6
DELISTED
Adamas Pharmaceuticals
ADMS
| $4.33M | 3.45% |
256,031
+31,700
| +14% | +$490K |
|
|
7
Alnylam Pharmaceuticals
ALNY
$27.5B
| $4.12M | 3.28% |
+110,000
| New | +$4.61M |
|
8
JPMorgan Chase
JPM
$935B
| $4.06M | 3.23% |
47,000
+10,625
| +29% | +$810K |
|
9
Amazon
AMZN
$2.92T
| $3.81M | 3.03% |
101,500
| – | – |
|
|
NVRO
10
DELISTED
NEVRO CORP.
NVRO
| $3.63M | 2.9% |
50,000
+2,200
| +5% | +$188K |
|
|
11
Aclaris Therapeutics
ACRS
$726M
| $3.56M | 2.83% |
131,000
+95,000
| +264% | +$2.42M |
|
12
Teekay
TK
$1.01B
| $3.28M | 2.61% |
408,275
| – | – |
|
|
13
Axogen
AXGN
$2.27B
| $3.17M | 2.53% |
352,000
+285,000
| +425% | +$2.46M |
|
|
HIMX
14
CALL
Himax Technologies
HIMX
$2.19B
| $3.08M | 2.46% |
550,000
| – | – |
|
|
15
Bank of America
BAC
$435B
| $2.76M | 2.2% |
+125,000
| New | +$2.41M |
|
16
NetEase
NTES
$85.3B
| $2.75M | 2.19% |
63,875
+7,500
| +13% | +$358K |
|
|
HDSN
17
Hudson Technologies
HDSN
$254M
| $2.68M | 2.14% |
335,000
+260,000
| +347% | +$1.84M |
|
|
MB
18
DELISTED
MINDBODY, Inc. Class A Common Stock
MB
| $2.57M | 2.05% |
120,698
| – | – |
|
19
NVIDIA
NVDA
$4.86T
| $1.92M | 1.53% |
720,000
| – | – |
|
|
BFYT
20
DELISTED
Benefytt Technologies, Inc. Class A Common Stock
BFYT
| $1.78M | 1.42% |
+100,000
| New | +$976K |
|
|
SOHU
21
Sohu.com
SOHU
$362M
| $1.74M | 1.39% |
51,300
+46,300
| +926% | +$1.73M |
|
22
Silicon Motion
SIMO
$8.6B
| $1.7M | 1.35% |
+40,000
| New | +$1.83M |
|
|
EVBG
23
DELISTED
Everbridge, Inc. Common Stock
EVBG
| $1.69M | 1.35% |
91,500
| – | – |
|
|
24
Sarepta Therapeutics
SRPT
$1.57B
| $1.65M | 1.31% |
60,000
-100,000
| -63% | -$4.02M |
|
25
Advanced Energy
AEIS
$11.6B
| $1.64M | 1.31% |
+30,000
| New | +$1.54M |
|
Similar funds
MAM
CCM
BGCI
CAM
EAM
SM
TPL
RC
Granite Point Capital Management's Q4 2016 Portfolio in Review
As of Q4 2016, Granite Point Capital Management held 112 positions worth $125M, down 51% from $256M the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Granite Point Capital Management withdrew a net $122M in Q4 2016, closing 32 positions and reducing 8 holdings. Its most notable exit was Apple, an estimated $4.91M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 26% of assets, up from 15% a quarter earlier, followed by Consumer Discretionary and Technology.
Against the trend, Granite Point Capital Management opened a new position in Alnylam Pharmaceuticals worth $4.12M.
- Granite Point Capital Management's largest Q4 2016 buy was Alnylam Pharmaceuticals: 110,000 shares worth $4.12M.
- Granite Point Capital Management added most to Axogen in Q4 2016, an estimated $2.46M increase.
- Granite Point Capital Management's biggest Q4 2016 reduction was Sarepta Therapeutics, cutting an estimated $4.02M.
- Granite Point Capital Management fully exited Apple in Q4 2016, selling an estimated $4.91M.
- Granite Point Capital Management's ten largest holdings make up 39% of its $125M portfolio in Q4 2016.
- Granite Point Capital Management opened 21 new positions and closed 32 in Q4 2016.
- Granite Point Capital Management's portfolio value fell 51% quarter-over-quarter to $125M.
Based on Granite Point Capital Management's 13F filing for Q4 2016, filed 7 Feb 2017.